Pharmacotherapeutic options for the treatment of preeclampsia

American Journal of Health-System Pharmacy

Volumn 66, Issue 4, 2009, Pages 337-344

  McCoy, Stagey ^a,b   Baldwin, Kathleen ^a  

^a WOLFSON CHILDREN S HOSPITAL   (United States)

^b BAPTIST MEDICAL CENTER   (United States)

Author keywords

Anticonvulsants; Hydralazine; Hypotensive agents; Labetalol; Magnesium sulfate; Mechanism of action; Methyldopa; Preeclampsia; Pregnancy; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATENOLOL; DIAZEPAM; DIPYRIDAMOLE; DIURETIC AGENT; ESMOLOL; HYDRALAZINE; LABETALOL; LORAZEPAM; MAGNESIUM SULFATE; METHYLDOPA; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITROPRUSSIDE SODIUM; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PLACEBO;

BEDTIME DOSAGE; BLOOD CLOTTING; BRADYCARDIA; BRAIN; BRAIN VASOSPASM; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DELIVERY; DIABETES MELLITUS; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; ECLAMPSIA; EPIGASTRIC PAIN; FETUS DISTRESS; FLUID RETENTION; FLUSHING; GESTATION PERIOD; HEADACHE; HEART PALPITATION; HEART RATE; HEMORRHAGIC PANCREATITIS; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOTENSION; INFLAMMATION; INTRACRANIAL PRESSURE; INTRAUTERINE GROWTH RETARDATION; ISCHEMIA; KIDNEY DISEASE; MATERNAL HYPERTENSION; MOTHER; NONHUMAN; OUTPATIENT; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK; RISK FACTOR; SEIZURE; SIDE EFFECT; SOLUTIO PLACENTAE; TACHYCARDIA; UTERINE CERVIX; VASCULAR DISEASE; VASODILATATION; FEMALE;

FEMALE; HUMANS; HYDRALAZINE; MAGNESIUM SULFATE; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 59849111929     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080104     Document Type: Review

References (66)

1. ACOG Committee on Practice Bulletins. ACOG practice bulletin. Chronic hypertension in pregnancy. Obstet Gynecol. 2001; 98(suppl):177-85.
2. ACOG Committee on Practice Bulletins. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2003; 102:203-13.
3. Wagner LK. Diagnosis and management of preeclampsia. Am Fam Physician. 2004; 70:2317-24.
4. Koonin LM, MacKay AP, Berg CJ et al. Pregnancy-related mortality surveillance-United States, 1987-1990. MMWR CDC Surveill Summ. 1997;46:17-36.
5. Vidaeff AC, Carroll MA, Ramin SM. Acute hypertensive emergencies in pregnancy. Crit Care Med. 2005; 33(suppl 10):S307-12.
6. Waugh JJ, Clark TJ, Divakaran TG et al. Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy. Obstet Gynecol. 2004; 103:769-77.
7. Waugh I, Bell SC, Kilby MD et al. Urine protein estimation in hypertensive pregnancy: which thresholds and laboratory assay best predict clinical outcome? Hypertens Pregnancy. 2005; 24:291-302.
8. Meyer NL, Mercer BM, Friedman SA et al. Urinary dipstick protein: a poor predictor of absent or severe proteinuria. Am J Obstet Gynecol. 1994; 170(1, pt. 1):137-41.
9. Gribble RK, Fee SC, Berg RL. The value of routine urine dipstick screening for protein at each prenatal visit. Am J Obstet Gynecol. 1995; 173:214-7.
10. Higby K, Suiter CR, Phelps JY et al. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol. 1994; 171:984-9.
11. Longo SA, Dola CP, Pridjian G. Preeclampsia and eclampsia revisited. South Med J. 2003;96:891-9.
12. ACOG Committee on Practice Bulletins- Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002; 99:159-67.
13. Lubarsky SL, Barton JR, Friedman SA et al. Late postpartum eclampsia revisited. Obstet Gynecol. 1994; 83:502-5.
14. Chames MC, Livingston JC, Ivester TS et al. Late postpartum eclampsia: a preventable disease? Am J Obstet Gynecol. 2002; 186:1174-7.
15. Sibai BM, Ramadan MK, Chari RS et al. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol. 1995; 172(1, pt. l):125-9.
16. Pirani BB, Campbell DM, MacGillivray I. Plasma volume in normal first pregnancy. J Obstet Gynaecol Br Commonw. 1973; 80:884-7.
17. Hayashi TT. The effect of benemid on uric acid excretion in normal pregnancy and in pre-eclampsia. Am J Obstet Gynecol. 1957; 73:17-22.
18. Hayashi TT. Uric acid and endogenous creatinine clearances after normal and toxemic pregnancy. Am J Obstet Gynecol. 1957;73:23-9.
19. Katz M, Berlyne GM. Differential renal protein clearance in toxaemia of pregnancy. Nephron. 1974; 13:212-20.
20. Hinchey I, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334:494-500.
21. Arora A, Chowdhury D, Daga MK et al. Reversible posterior leukoencephalopathy syndrome: a report of 2 cases. Neurol India. 2001;49:311-3.
22. Maynard JR, Dreyer BE, Stemerman MB et al. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood. 1977; 50:387-96.
23. Barron WM, Heckerling P, Hibbard JU et al. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol. 1999; 94:364-70.
24. Barker P, Callander CC. Coagulation screening before epidural analgesia in pre-eclampsia. Anaesthesia. 1991; 46:64-7.
25. Beilin Y, Bodian CA, Haddad EM et al. Practice patterns of anesthesiologists regarding situations in obstetric anesthesia where clinical management is controversial. Anesth Analg. 1996;83:735-41.
26. Wee L, Sinha P, Lewis M. Central nerve block and coagulation: a survey of obstetric anaesthetists. Int J Obstet Anesth. 2002; 11:170-5.
27. Ramanathan J. Anesthetic considerations in preeclampsia. Clin Perinatol. 1991; 18:875-89.
28. Ramanathan J, Coleman P, Sibai B. Anesthetic modification of hemodynamic and neuroendocrine stress responses to cesarean delivery in women with severe preeclampsia. Anesth Analg. 1991; 73:772-9.
29. Ramanathan J, Sibai BM, Mabie WC et al. The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. Am J Obstet Gynecol. 1988; 159:650-4.
30. Rout CC, Rocke DA. Effects of alfentanil and fentanyl on induction of anaesthesia in patients with severe pregnancy- induced hypertension. Br J Anaesth. 1990; 65:468-74.
31. Thompson Micromedex. www.thompsonhc.com (accessed 2008 Dec 15).
32. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther. 2008;83:181-3.
33. Public Affairs Committee on the Teratology Society. Teratology Public Affairs Committee position paper: pregnancy labeling for prescription drugs: ten years later. Birth Defects Res A Clin Mol Teratol. 2007; 79:627-30.
34. Hydralazine package insert. Summit, NJ: CIBA Pharmaceutical Co.; 1995.
35. Magee LA, Cham C, Waterman EJ et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003; 327:955-60.
36. Labetalol hydrochloride package insert. San Diego, CA: Prometheus Laboratories; 2003.
37. Carbonne B, Jannet D, Touboul C et al. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol. 1993; 81:908-14.
38. Lambert CR, Hill JA, Nichols WW et al. Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol. 1985; 55:652-6.
39. Wallin JD, Fletcher E, Ram CV et al. Intravenous nicardipine for the treatment of severe hypertension. A double-blind, placebo-controlled multicenter trial. Arch Intern Med. 1989; 149:2662-9.
40. Cardene i.v. package insert. Deerfield, IL: Hoffmann-La Roche; 2006.
41. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest. 2000; 118:214-27.
42. Mansoor GA, Frishman WH. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis. 2002;4:358-71.
43. Schimmel MS, Eidelman AI, Wilschanski MA et al. Toxic effects of atenolol consumed during breast feeding. J Pediatr. 1989; 114:476-8. [Erratum, J Pediatr. 1990; 116:158.]
44. Tabacova SA, Kimmel CA. Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity. Reprod Toxicol. 2002; 16:1-7.
45. Ellsworth A. Pharmacotherapy of hypertension while breastfeeding. J Hum Lact. 1994; 10:121-4.
46. Procardia oral capsule package insert. New York: Pfizer; 1999.
47. Bannan LT, Beevers DG, Wright N. ABC of blood pressure reduction. Emergency reduction, hypertension in pregnancy, and hypertension in the elderly. Br Med J. 1980; 281:1120-2.
48. Brown MA, Buddie ML, Farrell T et al. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002; 187:1046-50.
49. Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol. 1994; 101:262-3.
50. Waisman GD, Mayorga LM, Cámera MI et al. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol. 1988; 159:308-9.
51. Altman D, Carroli G, Duley L et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo- controlled trial. Lancet. 2002; 359:1877-90.
52. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol. 1998;92:883-9.
53. Idama TO, Lindow SW. Magnesium sulphate: a review of clinical pharmacology applied to obstetrics. Br J Obstet Gynaecol. 1998; 105:260-8.
54. Cahill AG, Macones GA, Odibo AO et al. Magnesium for seizure prophylaxis in patients with mild preeclampsia. Obstet Gynecol. 2007; 110:601-7.
55. Livingston JC, Livingston LW, Ramsey R et al. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2003; 101:217-20.
56. Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1997; 176:623-7.
57. Belfort MA, Saade GR, Yared M et al. Change in estimated cerebral perfusion pressure after treatment with nimodipine or magnesium sulfate in patients with preeclampsia. Am J Obstet Gynecol. 1999; 181:402-7.
58. Belfort MA, Anthony J, Saade GR et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003; 348:304-11.
59. Azonobi I, McBride-Richter H, Patrick L. Late-onset postpartum eclampsia. J Midwifery Womens Health. 2006; 51:51-3.
60. Belogolovkin V, Levine SR, Fields MC et al. Postpartum eclampsia complicated by reversible cerebral herniation. Obstet Gynecol. 2006; 107(2, pt. 2):442-5.
61. Lakshmi R, Upreti D, Agrawal A et al. Late postpartum eclampsia at five weeks post-delivery. Singapore Med J. 2007; 48: 946-7.
62. Duley L, Henderson-Smart DJ, Meher S et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; 2:CD004659.
63. Askie LM, Duley L, Henderson-Smart DJ et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007; 369:1791-8.
64. Rumbold AR, Crowther CA, Haslam RR et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006; 354:1796-806.
65. Villar J, Abdel-Aleem H, Merialdi M et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol. 2006; 194:639-49.
66. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2006; 3:CD001059.